Takeda Pharmaceuticals Korea announced Wednesday that it has completed the acquisition process of Shire Korea by inheriting all rights and obligations.

Takeda Pharmaceuticals Korea appointed Moon Hee-seok as its CEO in January last year and approved the takeover of Shire Pharma Korea at a general shareholders' meeting in April.

With the completion of the acquisition procedure, Takeda Pharmaceuticals Korea took over the sales right of Shire Korea products, such as Agrylin, Firazyr Prefilled Syringe, and Mezavant XL, Replagal, Vpriv Injection, Advate injection, the company said.

"As the corporate integration process has been completed, we will step up efforts to supply innovative medicines to patients," CEO Moon said.

However, the management’s dispute with unionized workers seemed to be going on.

Most recently, the unionized workers of Takeda Korea took issue with the company's early retirement program (EPR) targeting employees engaged in the primary care business concerning its sell-off of business rights for 18 prescription and over-the-counter (OTC) drugs in the Asia-Pacific region to Celltrion on June 12.

Upon the announcement of the ERP program, the Korea Democratic Pharmaceutical Union (KDPU) to which unionized workers of Takeda Korea belong declared a war against the management of Takeda Korea.

"The company failed to put forth any measures for the employees in offering ERP as the only option," a union member said. "That showed the company views its employees as expendables."

corea022@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>